IP Verse

Compositions And Methods For Treating Anemia - EP3007695

The patent EP3007695 was granted to Akebia Therapeutics on Feb 7, 2024. The application was originally filed on Jun 4, 2014 under application number EP14811317A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3007695

AKEBIA THERAPEUTICS
Application Number
EP14811317A
Filing Date
Jun 4, 2014
Status
Granted And Under Opposition
Jan 5, 2024
Grant Date
Feb 7, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZNov 6, 2024TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2007299086
EXAMINATIONWO03053997
INTERNATIONAL-SEARCH-REPORTUS2007299086
INTERNATIONAL-SEARCH-REPORTUS2012309977
INTERNATIONAL-SEARCH-REPORTUS2014057892
OPPOSITIONUS2007299086
OPPOSITIONWO2014200773
SEARCHUS2007299086

Non-Patent Literature (NPL) Citations (17) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- JENS T. CARSTENSEN, Drug Stability: Principles & Practice, Marcel Dekker, (19950000), pages 379 - 80
DESCRIPTION- Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
DESCRIPTION- SHETA et al., Oncogene, (20011115), vol. 20, no. 52, pages 7624 - 34
INTERNATIONAL-SEARCH-REPORT- "AKEBIA CLOSES $41 MILLION SERIES C", (20130604), pages 1 - 2, URL: hftp://www.tmvp.com/news_Akebia_06042013.html, XP026740630
INTERNATIONAL-SEARCH-REPORT- "CLINICALTRIALS.GOV: ARCHIVE: NCT01235936 Nn 2012_09_30", (20120830), pages 1 - 3, URL: http://clinicaltrials.gov/archive/NCT01235936/2012_09_30, XP055328354
INTERNATIONAL-SEARCH-REPORT- PASQUALETTI, P ET AL., "Circadian Rhythm Of Serum Erythropoietin In Myelodysplastic Syndromes.", EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES., (2000), vol. 4, pages 111 - 115, XP055303710
INTERNATIONAL-SEARCH-REPORT- STOHLAWETZ, PJ ET AL., "Effects Of Erythropoietin On Platelet Reactivity And Thrombopoiesis In Humans.", BLOOD., (2000), vol. 95, no. 9, pages 2983 - 2989, XP002481264
OPPOSITION- Akebia, "AKEBIA ANNOUNCES POSITIVE RESULTS FOR AKB-6548 PHASE 2A CLINICAL STUDY -Findings support once daily dosing; no serious adverse events", (20101005), pages 1 - 2, XP093241296
OPPOSITION- Akebia, "Akebia Closes $41 Million Series C --Proceeds to Support Phase 2b Trial and Phase 3 Preparations for Promising Anemia Drug Candidate", (20130604), (20170125), XP055339050
OPPOSITION- Anonymous, "ANNEX I - SUMMARY OF PRODUCT CHARACTERISTICS - Vafseo, INN-vadadustat", EMA - European Medicines Agency, (20230424), pages 1 - 37, EMA - European Medicines Agency, URL: https://www.ema.europa.eu/en/documents/product-information/vafseo-epar-product-information_en.pdf, XP093238114
OPPOSITION- Simon Beuck, Wilhelm Schänzer, Mario Thevis, "Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis", Drug Testing and Analysis, (20121124), vol. 4, no. 11, doi:10.1002/dta.390, ISSN 19427603, pages 830 - 845, XP055154645
OPPOSITION- Michael H. Rabinowitz, Terrance D. Barrett, Mark D. Rosen, Hariharan Venkatesan, "Inhibitors of HIF Prolyl Hydroxylases", ANNUAL REPORTS IN MEDICINAL CHEMISTRY, US, (20100101), vol. 45, doi:10.1016/S0065-7743(10)45008-3, ISSN 0065-7743, pages 123 - 139, XP009180487
OPPOSITION- Chertow Glenn M., Pergola Pablo E., Farag Youssef M.K., Agarwal Rajiv, Arnold Susan, Bako Gabriel, Block Geoffrey A., Burke Steven, Castillo Fausto P., Jardine Alan G., Khawaja Zeeshan, Koury Mark J., Lewis Eldrin F., Lin Tim, Luo Wenli, Maroni Bradley J., Matsushita Kunihiro, Mccullough Peter A., Parfrey Patrick S., Roy-Chaudhury Prabir, Sarnak Mark J., Sharma Amit, Spinowitz Bruce, Tseng Carol, Tumlin James, Vargo Dennis L., Walters Kimberly A., Winkelmayer Wolfgang C., Wittes Janet, Eckardt Kai-Uwe, "Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD", The New England journal of medicine, US , (20210429), vol. 384, no. 17, doi:10.1056/NEJMoa2035938, ISSN 0028-4793, pages 1589 - 1600, XP093241179
OPPOSITION- Myllyharju Johanna, "Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets", Annals of Medicine, SE, (20080108), vol. 40, no. 6, doi:10.1080/07853890801986594, ISSN 0785-3890, pages 402 - 417, XP055922838
OPPOSITION- Mimura Imari, Tanaka Tetsuhiro, Nangaku Masaomi, "Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney disease", Expert Opin Pharmacother, GB, (20240612), vol. 25, no. 9, doi:10.1080/14656566.2024.2370896, ISSN 1465-6566, pages 1111 - 1120, XP093241183
OPPOSITION- Schmid Holger, Schiff L Helmut, R. Lederer Stephan, "New Strategies for Managing Anemia of Chronic Kidney Disease", CARDIOVASCULAR & HEMATOLOGICAL AGENTS IN MEDICINAL CHEMISTRY, NL, (20121001), vol. 10, no. 4, doi:10.2174/187152512803530342, ISSN 1871-5257, pages 339 - 351, XP093241282
SEARCH- Akebia, "Akebia Closes $41 Million Series C --Proceeds to Support Phase 2b Trial and Phase 3 Preparations for Promising Anemia Drug Candidate", (20130604), URL: http://files.shareholder.com/downloads/AMDA-2MD7AT/0x0x733748/5e5822e6-2bcd-4969-ab79-0d298fee5066/733748.pdf, (20170125), XP055339050 [X] 1-25,30-32 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents